RSS/PSI journal webinar: Adaptive signature designs

 
Share Download as iCal file
Click the icons above to Share, Tweet or add this event to your calendar (iCal)
 
RSS Webinar Series

Wednesday 12 July 2017, 02:30pm

 
Location Online

wiley-logoPSI logo

Once a year, the RSS and PSI hold a joint webinar and this year’s joint event will follow the theme of 'adaptive signature design'.

Joint webinars focus on one key paper from the PSI, one from the RSS Journals. One or more discussants are also invited to join.

RSS author & paper: 

Zhiwei Zhang, 'Subgroup Selection in Adaptive Signature Designs of Confirmatory Clinical Trials', published February 2017 in JRSS Series C, Volume 2.

Co-authored by Meijuan Li, Min Lin, Guoxing Soon, Tom Greene and Changyu Shen.

Abstract: The increasing awareness of treatment effect heterogeneity has motivated flexible designs of confirmatory clinical trials that prospectively allow investigators to test for treatment efficacy for a subpopulation of patients in addition to the entire population. If a target subpopulation is not well characterized in the design stage, it can be developed at the end of a broad eligibility trial under an adaptive signature design. The paper proposes new procedures for subgroup selection and treatment effect estimation (for the selected subgroup) under an adaptive signature design. We first provide a simple and general characterization of the optimal subgroup that maximizes the power for demonstrating treatment efficacy or the expected gain based on a specified utility function. This characterization motivates a procedure for subgroup selection that involves prediction modelling, augmented inverse probability weighting and low dimensional maximization. A cross-validation procedure can be used to remove or reduce any resubstitution bias that may result from subgroup selection, and a bootstrap procedure can be used to make inference about the treatment effect in the subgroup selected. The approach proposed is evaluated in simulation studies and illustrated with real examples.

Dr Zhiwei Zhang is Associate Professor of Biostatistics at the University of California, Riverside. He received his PhD in Biostatistics from the University of Pittsburgh in 2004. Prior to his current position, he has worked at the US Food and Drug Administration (as Mathematical Statistician) and the US National Institutes of Health (as Investigator of Biostatistics). Dr. Zhang has done methodological research in many areas of biostatistics, including causal inference, precision medicine, and clinical trial design and analysis.

Presentation slides.

PSI author & paper

Gu Mi, 'Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial' published May 2017 in Pharmaceutical Statistics.

Abstract: Because of the complexity of cancer biology, often the target pathway is not well understood at the time that phase III trials are initiated. A 2-stage trial design was previously proposed for identifying a subgroup of interest in a learn stage, on the basis of 1 or more baseline biomarkers, and then subsequently confirming it in a confirmation stage. In this article, we discuss some practical aspects of this type of design and describe an enhancement to this approach that can be built into the study randomization to increase the robustness of the evaluation. Furthermore, we show via simulation studies how the proportion of patients allocated to the learn stage versus the confirm stage impacts the power and provide recommendations.

Dr Gu Mi is a Research Scientist at Eli Lilly and Company in Indianapolis, Indiana, USA. He received his PhD in statistics from Oregon State University in June 2014. He has been a clinical and biomarker statistician at Lilly Oncology with hands-on experience of oncology trials. He has been actively involved in trial designs, statistical methodology development in oncology, biomarker data analyses, and regulatory activities. He has been serving as an expert reviewer for eight peer-reviewed journals covering topics such as biopharmaceutical statistics, clinical trials, and bioinformatics.

Presentation slides.

Discussant
Dr Richard Simon has just retired as associate director of the Division of Cancer Treatment & Diagnosis and Chief of the Computational and Systems Biology Branch at the National Cancer Institute after many years there.

He has published extensively on the methodology of clinical trials and the analysis of high dimensional genomic data and is author of Using Genomics in Clinical Trials and Predictive Medicine and is the architect of the BRB-ArrayTools and BRB SeqTools software packages.

Dr Simon is the recipient of the 2013 Karl Peace award of the American Statistical Association and the 2017 Marvin Zelen award from Harvard University.

 

Chair
Steven Gilmour, Professor of Statistics at King’s College London, will chair the event. He research is mostly on the statistical theory, methodology and applications of the design and analysis of experiments. Much of his research is on experiments with complex treatment structures, such as those with many variables (factorial designs), those with continuous levels (especially leading to nonlinear models) and those with several continuous variables (response surface methodology). 

To join the webinar: http://mci-group.globalmeet.com/psijournalclub

 


Dial in using Phone: +44 (0) 330 336 6011 and Passcode: 497 034 0644 or connect audio from within GlobalMeet (‘Call my phone’ or ‘Call my computer’). Dial-in details for outside of the UK.

Contact Judith Shorten This email address is being protected from spambots. You need JavaScript enabled to view it.

Organiser Name Royal Statistical Society/PSI

Email Address This email address is being protected from spambots. You need JavaScript enabled to view it.

Organising Group(s) Royal Statistical Society/PSI

 

 

 

 

Join the RSS

Join the RSS

Become part of an organisation which works to advance statistics and support statisticians

Copyright 2019 Royal Statistical Society. All Rights Reserved.
12 Errol Street, London, EC1Y 8LX. UK registered charity in England and Wales. No.306096

Twitter Facebook YouTube RSS feed RSS feed RSS newsletter

We use cookies to understand how you use our site and to improve your experience. By continuing to use our site, you accept our use of cookies and Terms of Use.